MP78-07 THE IMPORTANCE OF OTHER CAUSE MORTALITY AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH METASTATIC PROSTATE CANCER EXPOSED TO CONVENTIONAL ANDROGEN DEPRIVATION THERAPY

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History III1 Apr 2014MP78-07 THE IMPORTANCE OF OTHER CAUSE MORTALITY AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH METASTATIC PROSTATE CANCER EXPOSED TO CONVENTIONAL ANDROGEN DEPRIVATION THERAPY Ioana Popa, Giorgio Gandaglia, Mounsif Azizi, Jonas Schiffmann, Vincent Trudeau, Nawar Hanna, Paul Perrotte, Quoc-Dien Trinh, Pierre I. Karakiewicz, and Maxine Sun Ioana PopaIoana Popa More articles by this author , Giorgio GandagliaGiorgio Gandaglia More articles by this author , Mounsif AziziMounsif Azizi More articles by this author , Jonas SchiffmannJonas Schiffmann More articles by this author , Vincent TrudeauVincent Trudeau More articles by this author , Nawar HannaNawar Hanna More articles by this author , Paul PerrottePaul Perrotte More articles by this author , Quoc-Dien TrinhQuoc-Dien Trinh More articles by this author , Pierre I. KarakiewiczPierre I. Karakiewicz More articles by this author , and Maxine SunMaxine Sun More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2490AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Recent reports indicated important cardiovascular (CV) morbidity and mortality in patients exposed to androgen deprivation therapy (ADT), especially in those with baseline CV comorbidities (Albertsen et al. Eur Urol 2013; in press). METHODS Patients aged 65 years and older with metastatic PCa who received ADT were abstracted from the Surveillance and Epidemiology and End Results (SEER) Medicare database, between 2000-2009. We examined the rates of cancer specific (CSM) and other cause mortality (OCM) in individuals with metastatic prostate cancer (PCa) exposed to ADT. Among OCM cases, we focused on deaths attributed to CV complications. Additionally, we repeated the analysis in patients with baseline CV comorbidities, since these individuals may be at highest risk of CV mortality when exposed to ADT. RESULTS Of 4,230 patients with metastatic PCa exposed to ADT the rates of OCM were 22.7% at five years compared to 55.6% for PCa mortality. Of individuals who died of OCM 496 (56.6%) deaths were attributed to CV causes. At baseline, 1,414 (33.4%) patients had CV comorbidities. When focusing exclusively on this sub-cohort, the 5-year OCM and CSM rates were 29.1% vs. 53.7%, respectively. Of the 373 (26.4%) deaths from other causes, 181 (48.5%) were attributed to CV causes. CONCLUSIONS As many as 1 in 4 deaths that occur in patients with metastatic PCa treated with ADT were attributable to OCM rather than PCa itself. Moreover, CV deaths occurred in half of patients dying from OCM. These observations emphasize the importance of comorbidities in this patient group. More specifically, baseline comorbidities were particularly important in patients with CV disease. In this subgroup, the rate of OCM was approximately 30%. Possibly, the introduction of new ADT agents such as LHRH blockers may reduce the risk of death from CV causes. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e923 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Ioana Popa More articles by this author Giorgio Gandaglia More articles by this author Mounsif Azizi More articles by this author Jonas Schiffmann More articles by this author Vincent Trudeau More articles by this author Nawar Hanna More articles by this author Paul Perrotte More articles by this author Quoc-Dien Trinh More articles by this author Pierre I. Karakiewicz More articles by this author Maxine Sun More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...